116 related articles for article (PubMed ID: 25692521)
1. Cost-utility analysis of an adjunctive recombinant activated factor VIIa for on-demand treatment of bleeding episodes in dengue haemorrhagic fever.
Naing C; Poovorawan Y; Mak JW; Aung K; Kamolratankul P
Blood Coagul Fibrinolysis; 2015 Jun; 26(4):403-7. PubMed ID: 25692521
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling.
Ballal RD; Botteman MF; Foley I; Stephens JM; Wilke CT; Joshi AV
Curr Med Res Opin; 2008 Mar; 24(3):753-68. PubMed ID: 18234151
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of using recombinant activated factor VII as an off-label rescue treatment for critical bleeding requiring massive transfusion.
Ho KM; Litton E
Transfusion; 2012 Aug; 52(8):1696-702. PubMed ID: 22211634
[TBL] [Abstract][Full Text] [Related]
4. Health economics in haemophilia: a review from the clinician's perspective.
Escobar MA
Haemophilia; 2010 May; 16 Suppl 3():29-34. PubMed ID: 20586799
[TBL] [Abstract][Full Text] [Related]
5. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea.
You CW; Lee SY; Park SK
Haemophilia; 2009 Jan; 15(1):217-26. PubMed ID: 18754800
[TBL] [Abstract][Full Text] [Related]
6. The use of recombinant activated factor VII for controlling life-threatening bleeding in Dengue Shock Syndrome.
Chuansumrit A; Tangnararatchakit K; Lektakul Y; Pongthanapisith V; Nimjaroenniyom N; Thanarattanakorn P; Wongchanchailert M; Komwilaisak P
Blood Coagul Fibrinolysis; 2004 Jun; 15(4):335-42. PubMed ID: 15166920
[TBL] [Abstract][Full Text] [Related]
7. Systematic literature review of economics analysis on treatment of mild-to-moderate bleeds with aPCC versus rFVIIa.
Hay JW; Zhou ZY
J Med Econ; 2011; 14(4):516-25. PubMed ID: 21699366
[TBL] [Abstract][Full Text] [Related]
8. Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors.
Hay JW; Zhou ZY
Haemophilia; 2011 Sep; 17(5):e969-74. PubMed ID: 21649802
[TBL] [Abstract][Full Text] [Related]
9. Bypass therapy assay testing as a strategy to reduce costs for treatment of haemophilia patients with inhibitors.
Hay JW; Chaugule SC; Young G
Haemophilia; 2013 Sep; 19(5):711-9. PubMed ID: 23672765
[TBL] [Abstract][Full Text] [Related]
10. Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study.
Chuansumrit A; Wangruangsatid S; Lektrakul Y; Chua MN; Zeta Capeding MR; Bech OM;
Blood Coagul Fibrinolysis; 2005 Nov; 16(8):549-55. PubMed ID: 16269927
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage.
Earnshaw SR; Joshi AV; Wilson MR; Rosand J
Stroke; 2006 Nov; 37(11):2751-8. PubMed ID: 17008607
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of recombinant factor VIIa for treatment of intracerebral hemorrhage.
Kissela BM; Eckman MH
BMC Neurol; 2008 May; 8():17. PubMed ID: 18489750
[TBL] [Abstract][Full Text] [Related]
13. aPCC vs. rFVIIa for the treatment of bleeding in patients with acquired haemophilia - a cost-effectiveness model.
Kim CH; Simmons SC; Bui CM; Jiang N; Pham HP
Vox Sang; 2019 Jan; 114(1):63-72. PubMed ID: 30499154
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain.
Jimenez-Yuste V; Núñez R; Romero JA; Montoro B; Espinós B
Haemophilia; 2013 Nov; 19(6):841-6. PubMed ID: 23758100
[TBL] [Abstract][Full Text] [Related]
15. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.
Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K
Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474
[TBL] [Abstract][Full Text] [Related]
16. Recombinant activated factor VII usage in life threatening hemorrhage: a pediatric experience.
Bhat S; Yadav SP; Anjan M; Dinand V; Sachdeva A
Indian J Pediatr; 2011 Aug; 78(8):961-8. PubMed ID: 21328080
[TBL] [Abstract][Full Text] [Related]
17. Cost-utility analysis of recombinant factor VIIa (NovoSeven) in six children with long-standing inhibitors to factor VIII or IX.
Ekert H; Brewin T; Boey W; Davey P; Tilden D
Haemophilia; 2001 May; 7(3):279-85. PubMed ID: 11380632
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of recombinant activated factor VII in nonhemophilia children with severe or life-threatening bleeding: a report from the SeveNBleeP registry.
Blatný J; Mathew P; Monagle P; Ovesna P; Fiamoli V
Blood Coagul Fibrinolysis; 2014 Jun; 25(4):326-32. PubMed ID: 24389586
[TBL] [Abstract][Full Text] [Related]
19. [Health economics of inhibitor bypassing agents in haemophilia A-activated prothrombin complex concentrate (aPCC) and recombinant activated factor VIIa (rFVIIa)].
Szmurło D; Deryło Ł; Ryś P; Władysiuk M
Pol Merkur Lekarski; 2011 Mar; 30(177):202-7. PubMed ID: 21544998
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of prophylactic treatment with activated prothrombin complex concentrate in a patient with inhibitor-positive hemophilia A.
Nakamura S; Morimoto A; Oh Y; Hayase T; Kashii Y; Gunji Y; Momoi MY
Blood Coagul Fibrinolysis; 2012 Apr; 23(3):235-7. PubMed ID: 22322137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
